BACKGROUND: Left ventricular assist device (LVAD) therapy improves the hemodynamics of advanced heart failure patients. However, it is unknown whether hemodynamic optimization improves clinical outcomes. The aim of this study was to investigate whether hemodynamic optimization reduces hospital readmission rate in LVAD patients. METHODS AND RESULTS: LVAD patients undergoing an invasive hemodynamic ramp test were prospectively enrolled and followed for 1 year. LVAD speed was optimized using a ramp test, targeting the following goals: central venous pressure <12 mm Hg, pulmonary capillary wedge pressure <18 mm Hg, and cardiac index >2.2 L/(min·m2). The frequency and cause of hospital readmissions were compared between patients who achieved (optimized group) or did not achieve (nonoptimized group) these goals. Eighty-eight outpatients (median 61 years old, 53 male) underwent ramp testing 236 days after LVAD implantation, and 54 (61%) had optimized hemodynamics after LVAD speed adjustment. One-year survival after the ramp study was comparable in both groups (89% versus 88%). The total hospital readmission rate was lower in the optimized group compared with the nonoptimized group (1.15 versus 2.86 events/y, P<0.001). This result was predominantly because of a reduction in the heart failure readmission rate in the optimized group (0.08 versus 0.71 events/y, P=0.016). CONCLUSIONS: LVAD patients, in whom hemodynamics were optimized, had a significantly lower rate of hospital readmissions, primarily because of fewer heart failure admissions. These findings highlight the importance of achieving hemodynamic optimization in LVAD patients.
BACKGROUND: Left ventricular assist device (LVAD) therapy improves the hemodynamics of advanced heart failurepatients. However, it is unknown whether hemodynamic optimization improves clinical outcomes. The aim of this study was to investigate whether hemodynamic optimization reduces hospital readmission rate in LVADpatients. METHODS AND RESULTS:LVADpatients undergoing an invasive hemodynamic ramp test were prospectively enrolled and followed for 1 year. LVAD speed was optimized using a ramp test, targeting the following goals: central venous pressure <12 mm Hg, pulmonary capillary wedge pressure <18 mm Hg, and cardiac index >2.2 L/(min·m2). The frequency and cause of hospital readmissions were compared between patients who achieved (optimized group) or did not achieve (nonoptimized group) these goals. Eighty-eight outpatients (median 61 years old, 53 male) underwent ramp testing 236 days after LVAD implantation, and 54 (61%) had optimized hemodynamics after LVAD speed adjustment. One-year survival after the ramp study was comparable in both groups (89% versus 88%). The total hospital readmission rate was lower in the optimized group compared with the nonoptimized group (1.15 versus 2.86 events/y, P<0.001). This result was predominantly because of a reduction in the heart failure readmission rate in the optimized group (0.08 versus 0.71 events/y, P=0.016). CONCLUSIONS:LVADpatients, in whom hemodynamics were optimized, had a significantly lower rate of hospital readmissions, primarily because of fewer heart failure admissions. These findings highlight the importance of achieving hemodynamic optimization in LVADpatients.
Entities:
Keywords:
blood pressure; central venous pressure; heart failure; hemodynamics; patients
Authors: Jonathan D Rich; Igor Gosev; Chetan B Patel; Susan Joseph; Jason N Katz; Peter M Eckman; Sangjin Lee; Kartik Sundareswaran; Ahmet Kilic; Brian Bethea; Behzad Soleimani; Brian Lima; Nir Uriel; Michael Kiernan Journal: J Heart Lung Transplant Date: 2016-08-20 Impact factor: 10.247
Authors: Simon Maltais; Keith D Aaronson; Jeffrey J Teuteberg; Mark S Slaughter; Samer S Najjar; Valluvan Jeevanandam; Duc T Pham; Edwin C McGee; Katrin Leadley; Robert L Kormos Journal: ASAIO J Date: 2017 Nov/Dec Impact factor: 2.872
Authors: Karima Addetia; Nir Uriel; Francesco Maffessanti; Gabriel Sayer; Sirtaz Adatya; Gene H Kim; Nitasha Sarswat; Savitri Fedson; Diego Medvedofsky; Eric Kruse; Keith Collins; Daniel Rodgers; Takayoshi Ota; Valluvan Jeevanandam; Victor Mor-Avi; Daniel Burkhoff; Roberto M Lang Journal: JACC Cardiovasc Imaging Date: 2017-04-12
Authors: Nir Uriel; Gabriel Sayer; Karima Addetia; Savitri Fedson; Gene H Kim; Daniel Rodgers; Eric Kruse; Keith Collins; Sirtaz Adatya; Nitasha Sarswat; Ulrich P Jorde; Colleen Juricek; Takeyoshi Ota; Valluvan Jeevanandam; Daniel Burkhoff; Roberto M Lang Journal: JACC Heart Fail Date: 2015-12-30 Impact factor: 12.035
Authors: Nir Uriel; Kerry A Morrison; Arthur R Garan; Tomoko S Kato; Melana Yuzefpolskaya; Farhana Latif; Susan W Restaino; Donna M Mancini; Margaret Flannery; Hiroo Takayama; Ranjit John; Paolo C Colombo; Yoshifumi Naka; Ulrich P Jorde Journal: J Am Coll Cardiol Date: 2012-10-03 Impact factor: 24.094
Authors: Tal Hasin; Yariv Marmor; Walter Kremers; Yan Topilsky; Cathy J Severson; John A Schirger; Barry A Boilson; Alfredo L Clavell; Richard J Rodeheffer; Robert P Frantz; Brooks S Edwards; Naveen L Pereira; John M Stulak; Lyle Joyce; Richard Daly; Soon J Park; Sudhir S Kushwaha Journal: J Am Coll Cardiol Date: 2012-12-05 Impact factor: 24.094
Authors: Ruben E Hernandez; Steve K Singh; Dale T Hoang; Syed W Ali; MacArthur A Elayda; Hari R Mallidi; O H Frazier; Deborah E Meyers Journal: Tex Heart Inst J Date: 2015-10-01
Authors: Christos P Kyriakopoulos; Chris J Kapelios; Elizabeth L Stauder; Iosif Taleb; Rana Hamouche; Konstantinos Sideris; Antigone G Koliopoulou; Michael J Bonios; Stavros G Drakos Journal: J Clin Med Date: 2022-06-20 Impact factor: 4.964